RESUMO
BACKGROUND: Erectile dysfunction represents an important health problem and the instrument most frequently used for the evaluation of its evaluation is the International Index of Erectile Function (IIEF-5). AIM: Due to lack of adaptation and validation for Spanish-speaking populations, this study aimed to adapt and validate the Colombian version of International Index of Erectile Function (IIEF-5). METHODS: Two independent samples were evaluated. One used to validate the scale and the other to calculate cut-off point of this version, with 2,021 men from the general population and outpatients from a clinic. The age range was 18 to 75 years old (M = 37.80; SD = 14.06). The second sample included 74 men, 64.9% did not meet DSM-5 criteria for erectile dysfunction, and 35.1% meet DSM-5 criteria to ED. Age range was 19 to 73 years old (M = 40.38; SD = 13.22). OUTCOMES: All participants answered the Spanish versions of the International Index of Erectile Function-5 (IIEF-5) and the Massachusetts General Health-Sexual Functioning Questionnaire. RESULTS: The Colombian version of IIEF-5 showed adequate psychometric properties, confirmed the one-dimension factorization of the scale, and showed adequate evidence of reliability and validity. Significant differences were observed in the IIEF-5 total score between the non-clinical and clinical groups who meet DSM-5 criteria for erectile dysfunction, with a large effect size. Also, the cut-off the Colombian version was set to 16, with an area under the curve of 94.9%. CLINICAL IMPLICATIONS: The Colombian version of the IIEF-5 is a useful evaluation instrument that provides to determine the presence of erectile dysfunction compatible with DSM-5 criteria. STRENGTHS & LIMITATIONS: The inventory reports adequate psychometric properties, a confirmed one-dimensional structure, evidence of reliability and validity, and the first cut-off point for Hispanic populations. A more in-depth evaluation of the diagnosis of ED and thus replication in other Spanish-speaking countries and sexual minorities is recommended. CONCLUSION: The Spanish version of the IIEF-5 is a useful evaluation tool for identifying erectile dysfunction, following DSM-5 criteria. Vallejo-Medina P, Saffon JP, Álvarez-Muelas A Colombian Clinical Validation of the International Index of Erectile Function (IIEF-5). Sex Med 2022;10:100461.
RESUMO
OBJECTIVE: To determine the prevalence and factors associated with high-grade ED in Lima, Peru. MATERIAL AND METHODS: Analytical cross-sectional study in tuberculosis patients treated in an out patient clinic of a public hospital in Lima, Peru in 2018. High grade SD was the dependent variable, using the IIEF-5 questionnaire and the independent variables were sexual orientation, history of previous pathology, location of tuberculosis, type of treatment scheme and presence of hemoptysis. Prevalence ratios (PR) were estimated using simple and multiple regression models. RESULTS: Of 189 patients, the majority presented pulmonary tuberculosis (98.9%), overweight (25.9%) and just over half had high-grade ED (52.9%). In the simple regression it was found that the factors associated with presenting high-grade SD were age in years (RP=1.11), reporting diabetes (RP=2.09), having multi-drug resistant TB (RP=1.51) and presenting a treatment time from 1 year to more (RP=1.87). In the multiple regression, the variables that were associated with a higher frequency of high-grade TB were age in years (RP=1.11), a history of diabetes (RP=1.66) and having MDR TB (RP=2.04). CONCLUSIONS: This study suggests a high prevalence of ED in patients with TB, where four out of ten presented high-grade ED. Being older, having a history of diabetes and using an MDR treatment were positively associated with the development of high-grade ED. Studies with designs close to causality are required to know the real magnitude of the influence of clinical and therapeutic characteristics on the development of high-grade ED.
OBJETIVO: Determinar la prevalencia y factores asociados a DE (disfunción eréctil) alto grado en Lima, Perú.MATERIAL Y MÉTODOS: Estudio transversal analítico en pacientes tuberculosos atendidos en consultorio externo de un hospital público de Lima, Perú en el 2018. La DE alto grado fue la variable dependiente, utilizando el cuestionario IIEF-5 y las variables independientes fueron la orientación sexual, historia de patología previa, localización de tuberculosis, tipo de esquema de tratamiento y presencia de hemoptisis. Se estimaron razones de prevalencia (RP) utilizando modelos de regresión simple y múltiple. RESULTADOS: De 189 pacientes, la mayoría presentaba tuberculosis pulmonar (98,9%), sobrepeso (25,9%) y poco más de la mitad tuvo DE alto grado (52,9%). En la regresión simple se encontró que los factores asociados a presentar DE alto grado fueron la edad en años (RP=1,11), reportar diabetes (RP=2,09), tener TB multidrogo-resistente (RP=1,51) y presentar un tiempo de tratamiento de 1 año a más (RP=1,87). En la regresión múltiple, las variables que se asociaron a una mayor frecuencia de TB alto grado fueron la edad en años (RP=1,11), el antecedente de diabetes (RP=1,66) y tenerTB MDR (tuberculosis multirresistente) (2,04). CONCLUSIONES: Este estudio sugiere una alta prevalencia de DE en pacientes con TB, donde cuatro de cada diez presentaron DE alto grado. Tener mayor edad, presentar antecedente de diabetes y utilizar untratamiento MDR se asociaron positivamente al desarrollo de DE alto grado. Se requieren estudios con diseños cercanos hacia la causalidad para conocer la magnitud real de la influencia de características clínicas y terapéuticas en el desarrollo de DE alto grado.
Assuntos
Disfunção Erétil , Tuberculose , Estudos Transversais , Feminino , Hospitais , Humanos , Masculino , Peru , PrevalênciaRESUMO
OBJECTIVE: To assess the prevalence and risk factors of erectile dysfunction (ED) in HIV patients from the HIV clinic of a tertiary referral center in Mexico City. DESIGN: Prevalence was obtained from cross-sectional studies, and the International Index of Erectile Function (IIEF), a standardized method, was used to assess ED. METHODS: A cross-sectional study was performed in the HIV clinic. Participants completed the IIEF to allow ED assessment. Information on demographics, clinical and HIV-related variables was retrieved from their medical records. RESULTS: One hundred and nine patients were included, with a mean age of 39.9 ± 8.8 years. ED was present in 65.1% of the individuals. Patients had been diagnosed with HIV for a mean of 92.7 ± 70.3 months and had undergone a mean 56.4 ± 45.5 months of HAART. The only variable associated with ED in the univariate analysis was dyslipidemia, and this association was also found in the multivariate analysis (P = 0.01). CONCLUSIONS: ED is highly prevalent in HIV patients. Dyslipidemia should be considered as a risk factor for ED in HIV patients. Romero-Velez G, Lisker-Cervantes A, Villeda-Sandoval CI, Sotomayor de Zavaleta M, Olvera-Posada D, Sierra-Madero JG, Arreguin-Camacho LO, and Castillejos-Molina RA. Erectile dysfunction among HIV patients undergoing highly active antiretroviral therapy: Dyslipidemia as a main risk factor. Sex Med 2014;2:24-30.
RESUMO
INTRODUCTION: Naturalistic clinical trials provide data on the effectiveness of drugs in nonexperimental and everyday situations and are extremely helpful for decision-making purposes and for confirming experimental findings in clinical trials. No data have been published from naturalistic studies performed in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) with or without erectile dysfunction (ED) and treated with phosphodiesterase type 5 inhibitors. AIM: The aim of this study (TadaLutsEd Study) was to assess, in the context of medical practice, the effectiveness of tadalafil 5 mg once daily in patients with LUTS/BPH with or without erectile dysfunction. METHODS: The study was a 6-week uncontrolled, prospective, open-label, multicentric, observational study. The patient population involved sexually active males aged ≥ 50 years, diagnosed with LUTS/BPH with or without concomitant ED, and treated with tadalafil 5 mg daily in accordance with standard urological practice. MAIN OUTCOME MEASURES: Effectiveness was assessed through the self-administered International Prostate Symptom Score (IPSS) questionnaire; quality of life was evaluated through the IPSS quality of life section (IPSS-QoL). The patients were also evaluated with the International Index of Erectile Function (IIEF-5). Adverse events were recorded. Statistical analyses using paired data samples was applied (Wilcoxon signed-ranks test). RESULTS: Sixty-two patients (mean age 62.2 years) completed the treatment, of whom 85.5% showed improvement in their urinary symptoms. Pre- and post-treatment differences in the IPSS, IPSS-QoL, and IIEF-5 scores were statistically significant at 4.4, 1, and 5.4 points, respectively (P < 0.0001). Tadalafil was well tolerated, and adverse events were mild, with a discontinuation rate of 1.6%. CONCLUSION: According to study results, the use of tadalafil 5 mg once daily in a nonselected patient population with LUTS/BPH with or without ED led to improvements in terms of symptoms and quality of life and exhibited a safety profile similar to that obtained in controlled tadalafil clinical trials.